Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori
Hassan Tariq, 1, 2 Harish Patel, 1, 2 Muhammad Umar Kamal, 1 Naeem Abbas, 1, 2 Muhammad Ameen, 1 Sara Azam, 1 Kishore Kumar, 1, 2 Madhavi Ravi, 1, 2 Vamshidhar Vootla, 1, 2 Danial Shaikh, 1, 2 Vamsi Amanchi, 1 Ali N Hussain, 3 Jasbir Makker 1, 2 1Department of Medicine, BronxCare Health System, Bro...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-01-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/reevaluation-of-the-efficacy-of-first-line-regimen-for-helicobacter-py-peer-reviewed-article-CEG |
| _version_ | 1818505228666798080 |
|---|---|
| author | Tariq H Patel H Kamal MU Abbas N Ameen M Azam S Kumar K Ravi M Vootla V Shaikh D Amanchi V Hussain AN Makker J |
| author_facet | Tariq H Patel H Kamal MU Abbas N Ameen M Azam S Kumar K Ravi M Vootla V Shaikh D Amanchi V Hussain AN Makker J |
| author_sort | Tariq H |
| collection | DOAJ |
| description | Hassan Tariq, 1, 2 Harish Patel, 1, 2 Muhammad Umar Kamal, 1 Naeem Abbas, 1, 2 Muhammad Ameen, 1 Sara Azam, 1 Kishore Kumar, 1, 2 Madhavi Ravi, 1, 2 Vamshidhar Vootla, 1, 2 Danial Shaikh, 1, 2 Vamsi Amanchi, 1 Ali N Hussain, 3 Jasbir Makker 1, 2 1Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA; 2Division of Gastroenterology, BronxCare Health System, Bronx, NY 10457, USA; 3Baruch College, City University of New York (CUNY), New York, NY 10010, USACorrespondence: Muhammad Umar KamalBronxCare Health System, 1650 Selwyn Ave, Suite #10C, Bronx, NY 10457, USATel +1 718-960-1234Fax +1 718-960-2055Email muhammadumarkamal@gmail.comBackground: Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge.Aim: There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population.Methods: This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy.Results: A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001).Conclusion: In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully.Keywords: Helicobacter pylori, clarithromycin, levofloxacin, quadruple therapy, peptic ulcer |
| first_indexed | 2024-12-10T21:47:51Z |
| format | Article |
| id | doaj.art-c750044525754e1ca63489b6b628d824 |
| institution | Directory Open Access Journal |
| issn | 1178-7023 |
| language | English |
| last_indexed | 2024-12-10T21:47:51Z |
| publishDate | 2020-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical and Experimental Gastroenterology |
| spelling | doaj.art-c750044525754e1ca63489b6b628d8242022-12-22T01:32:19ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232020-01-01Volume 13253351326Reevaluation of the Efficacy of First Line Regimen for Helicobacter pyloriTariq HPatel HKamal MUAbbas NAmeen MAzam SKumar KRavi MVootla VShaikh DAmanchi VHussain ANMakker JHassan Tariq, 1, 2 Harish Patel, 1, 2 Muhammad Umar Kamal, 1 Naeem Abbas, 1, 2 Muhammad Ameen, 1 Sara Azam, 1 Kishore Kumar, 1, 2 Madhavi Ravi, 1, 2 Vamshidhar Vootla, 1, 2 Danial Shaikh, 1, 2 Vamsi Amanchi, 1 Ali N Hussain, 3 Jasbir Makker 1, 2 1Department of Medicine, BronxCare Health System, Bronx, NY 10457, USA; 2Division of Gastroenterology, BronxCare Health System, Bronx, NY 10457, USA; 3Baruch College, City University of New York (CUNY), New York, NY 10010, USACorrespondence: Muhammad Umar KamalBronxCare Health System, 1650 Selwyn Ave, Suite #10C, Bronx, NY 10457, USATel +1 718-960-1234Fax +1 718-960-2055Email muhammadumarkamal@gmail.comBackground: Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge.Aim: There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population.Methods: This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy.Results: A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001).Conclusion: In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully.Keywords: Helicobacter pylori, clarithromycin, levofloxacin, quadruple therapy, peptic ulcerhttps://www.dovepress.com/reevaluation-of-the-efficacy-of-first-line-regimen-for-helicobacter-py-peer-reviewed-article-CEGhelicobacter pyloriclarithromycinlevofloxacinquadruple therapypeptic ulcer |
| spellingShingle | Tariq H Patel H Kamal MU Abbas N Ameen M Azam S Kumar K Ravi M Vootla V Shaikh D Amanchi V Hussain AN Makker J Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori Clinical and Experimental Gastroenterology helicobacter pylori clarithromycin levofloxacin quadruple therapy peptic ulcer |
| title | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori |
| title_full | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori |
| title_fullStr | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori |
| title_full_unstemmed | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori |
| title_short | Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori |
| title_sort | reevaluation of the efficacy of first line regimen for helicobacter pylori |
| topic | helicobacter pylori clarithromycin levofloxacin quadruple therapy peptic ulcer |
| url | https://www.dovepress.com/reevaluation-of-the-efficacy-of-first-line-regimen-for-helicobacter-py-peer-reviewed-article-CEG |
| work_keys_str_mv | AT tariqh reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT patelh reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT kamalmu reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT abbasn reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT ameenm reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT azams reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT kumark reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT ravim reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT vootlav reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT shaikhd reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT amanchiv reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT hussainan reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori AT makkerj reevaluationoftheefficacyoffirstlineregimenforhelicobacterpylori |